Precipio Inc Stock Price, News & Analysis

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q2-2025 shareholder update conference call for August 14th, 2025 at 5:00 PM ET. The call will provide updates on the company's core business segments.

Shareholders can access the call by dialing 800.717.1738. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call through Precipio's investor relations website.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has restructured its warrant agreement with its largest warrant holder. Under the new agreement, 100,000 warrants will be exercised for cash, while the remaining 200,000 warrants will be exercised cashlessly.

The restructuring results in two key outcomes: 1) A reduction in share dilution, with total new shares decreasing from ~300,000 to ~130,000-150,000, and 2) A reduced cash inflow of $1.2 million instead of the original $3.8 million. Management will discuss this transaction during their upcoming quarterly shareholder call around August 15th, 2025.

Precipio (NASDAQ: PRPO) is urgently requesting shareholders to vote their shares by 11 PM ET on June 16, 2025, ahead of their Annual Shareholders Meeting scheduled for June 17, 2025. Currently, only 42% of shares have been voted, falling short of the 50% quorum requirement. The company warns that failing to reach quorum would force meeting adjournment, potentially incurring significant costs of up to $100,000 for rescheduling, compared to the current meeting cost of less than $5,000. These additional expenses would include hiring a proxy solicitor, legal fees, and administrative costs. Management emphasizes that shareholders can vote either for or against, but voting participation is crucial to avoid unnecessary expenditures.

Precipio (NASDAQ: PRPO) reported strong Q1-2025 financial results with revenues reaching $4.9M, a 43% YoY increase. The company saw significant improvements in key metrics: - Adjusted EBITDA improved 92% YoY to ($108K) - Cash used in operations improved 93% YoY to ($44K) - Overall gross margins increased from 27% to 43% YoY - Operating expenses dropped from 87% to 61% of net revenue The Pathology Services division grew 54% YoY with 46% increase in test volume, while the Products division successfully onboarded new customers and launched new panels. The company expects to return to positive cash flow by Q2/Q3 2025, supported by a $400K non-recurring income from CARES Act and MolDx approval for NGS testing enabling Medicare billing.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q1-2025 shareholder update conference call for May 15th, 2025 at 5:00 PM ET. The call will provide updates on all of the company's core businesses.

Shareholders can access the call by dialing 844-695-5519 (international: 1-412-902-6760) or pre-register at the provided link to receive direct dial-in details. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call on Precipio's investor relations website.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q4 and year-end 2024 shareholder update conference call for March 31st, 2025 at 5:00 PM EST. The call will provide updates on all of the company's core businesses.

Shareholders can access the call through:

• Dial-in: 844-695-5519 (US) or 1-412-902-6760 (International)
• Pre-registration link: https://dpregister.com/sreg/10197585/fea81a2627

Investors can submit questions in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call on Precipio's investor relations website.

Precipio (NASDAQ: PRPO) has achieved two significant financial milestones in Q4-2024, demonstrating progress toward financial independence. The company reported positive Adjusted EBITDA of $0.4M and a cash flow increase of $0.3M (unaudited).

Of the cash flow improvement, $75,000 came from directors' fees paid in stock, with the remainder from operations. The company's pathology service division is now generating sufficient positive cash flow to fund ongoing R&D and investment in the high-value product business.

Management acknowledges potential quarterly fluctuations between positive and negative performance, particularly noting Q1 challenges due to insurance deductible renewals. However, with current cash reserves and growth pipeline, the company believes it's positioned to achieve sustained profitability.

Precipio (NASDAQ: PRPO) announced a significant change in its executive compensation structure, implementing performance-based stock options for senior management. The new options will only vest when the company's 10-day VWAP exceeds $30.30 per share, representing a 5x increase from the exercise price of $6.06. Unlike traditional time-based vesting, these options have no time restrictions and will only vest upon reaching the price target.

The entire senior management team, consisting of six individuals, voluntarily chose this performance-based structure over the traditional time-based vesting, demonstrating their confidence in the company's growth potential. Regular employees will continue with time-based vesting options. CEO Ilan Danieli expressed confidence that the share price target could be achieved in less than four years, while Chairman Richard Sandberg noted that this structure applies to leadership members most capable of impacting company performance.

Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, announces its Q3-2024 shareholder update conference call scheduled for November 18, 2024, at 5:00 PM EST. The call will discuss the company's Q3-2024 10-Q filing and provide financial highlights and analysis of core businesses. Shareholders can access the call via phone (844-695-5519 for domestic, 1-412-902-6760 for international) or pre-register online. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available on Precipio's website approximately 24 hours after the call.